About this trial
The goal of this observational study is to test the association between high levels of Galectin-3 and the occurrence of post-operative atrial fibrillation after isolated coronary artery bypass grafting (CABG). The main question\[s\] it aims to answer are:
* Is Galectin-3 an accurate biomarker to predict higher risk of developing post-operative atrial fibrillation? * Are high levels of Galectin-3 associated to other post-operative complications and major adverse cardiovascular events? Participants will be enrolled during pre-operative evaluation and a peripheral blood sample collection will be performed in the 24h before CABG. Participants will then be followed for a period of 12 months (daily during hospitalization and 3 appointments after hospital discharge) to determine whether patients with higher levels of Galectin-3 will have worse outcomes.
Eligibility criteria
Qualifiers
Patients undergoing coronary artery bypass graft surgery
Disqualifiers
Inability to sign the free and informed consent form
Renal dysfunction with estimated glomerular filtration rate less than 30ml / min / 1.73m² or dialysis therapy
Moderate to severe left ventricular dysfunction (ejection fraction < 40%)
Patients with previous atrial fibrillation
Trial design
Treatments tested in this trial
- Galectin-3 dosage